An open label, multicenter, dose-escalation, phase 1B/2 study of the safety, efficacy, pharmacodynamics, and pharmacokinetics of RTA 408 in combination with IPILIMUMAB in the treatment of patients with unresectable or metastatic melanoma

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2014 - September 16, 2019